Paired Central and Peripheral Blood Cultures for Febrile Neutropenia in Pediatric Patients With Cancer: Do We Need Peripheral Blood Cultures? This study utilized deidentified patient data from the ...

Adjuvant treatment following resection of stage III melanoma is standard practice, based largely on trials that showed it improves recurrence-free survival. However, oncologists have long wondered ...

Of 30 patients with resectable stage III melanoma treated with neoadjuvant nivolumab and relatlimab, 87% were alive and 80% remained disease-free after 4 years. Almost every patient who achieved a ...

ATHENS, Greece — Real-world data confirm that complete nodal dissection following a positive sentinel lymph node biopsy in patients with stage III melanoma and micrometastases does not significantly ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new ...

Droplet digital PCR measurements of ctDNA may accurately identify patients with melanoma who are at high risk of recurrence. Patients who were ctDNA positive had worse recurrence-free and overall ...

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...

Explore the latest statistics on cutaneous melanoma: why incidence rates are rising by 1.2% annually while mortality is dropping, and how biomarkers are driving personalized care. Cutaneous melanoma ...

This study utilized deidentified patient data from the National Cancer Database (NCDB). The data are not publicly available but can be accessed through application to the NCDB by eligible ...